linjc16/ctgov huggingface dataset:
Glenoid Bone Grafting for RTSA: Clinical & Radiographic Outcomes

Study Overview
=================
Brief Summary
-----------------
This study will look at patient radiographic and functional outcomes who have or will undergo a reverse, extended peg, shoulder arthroplasty (replacement) that requires the use of glenoid bone grafting.

Detailed Description
-----------------
Glenoid bone loss is a known issue with reverse shoulder implants and can lead to issues with implant fixation and stability over time. To address this issue an extended peg glenoid baseplate is used and area around plate is augmented with bone (auto or allo)graft material to encourage bony callous growth around the implant. This study is to look at this area of concern and determine if glenoid bone loss is occurring in the patients where these measures have been taken to deter its development.

Official Title
-----------------
Glenoid Bone Grafting for Reverse Shoulder Arthroplasty: Clinical and Radiographic Outcomes

Conditions
-----------------
Osteo Arthritis Shoulders

Intervention / Treatment
-----------------
* Diagnostic Test: CT Scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients who have undergone a reverse shoulder arthroplasty with the an extended peg baseplate and structural bone graft (autograft humeral head or allograft femoral head). Adult patients who are indicated for a long-pegged baseplate and glenoid bone grafting (autograft humeral head or allograft femoral head) as part of their reverse shoulder arthroplasty in our clinic, bone graft is truly structural involving at least 50% of the glenoid baseplate may be a primary or a revision surgery Exclusion Criteria: patients with missing baseline (preop) data, patients who are unwilling to participate in a final follow-up evaluation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: CT Scan|CT scan at minimum 1 year post op|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiographic Outcome | Evaluate Bone Graft Incorporation - review images to determine signs of humeral or glenoid radiolucency, radiographic loosening, fracture, notching, and graft incorporation versus resorption on CT and/or XRay images. | minimum 1 year post op | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional outcomes at year one | Evaluate postoperative clinical outcome scores | collected at 1 year post surgery | 
| Functional outcomes at year two | Evaluate postoperative clinical outcome scores | collected 2 years post surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
reverse total shoulder arthroplasty, glenoid bone loss
Open Trial of Family-Based Treatment for Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
This trial seeks to investigate the feasibility and effectiveness of delivering a newly manualized family-based treatment for adolescents with anorexia nervosa

Detailed Description
-----------------
This open trial seeks to investigate the feasibility and effectiveness of delivering a newly manualized family-based treatment for adolescents with anorexia nervosa at a site beyond the treatment's origin. Adolescents ages 12-17 with anorexia nervosa or subthreshold anorexia nervosa were treated with up to one year of this approach.

Official Title
-----------------
Pilot Study of Manualized Family Therapy for Adolescents With Anorexia Nervosa

Conditions
-----------------
Anorexia Nervosa

Intervention / Treatment
-----------------
* Behavioral: Family-Based Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 12-17 Diagnosis of full or subthreshold anorexia nervosa At least one parent or guardian willing to participate in treatment Exclusion Criteria: Bipolar Disorder, Psychotic Disorder, Substance Dependence Mental Retardation Acute suicidal risk Acute or unstable, poorly controlled chronic medical illness Weight below 75% ideal body weight

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Family therapy<br> | Behavioral: Family-Based Treatment<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight |  | end of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adolescents, Anorexia, Eating disorder, Family therapy
Bladder Diary for Diagnosing Bladder Oversensitivity

Study Overview
=================
Brief Summary
-----------------
Urodynamic study is an invasive procedure and applied for diagnosis of bladder oversensitivity. Bladder diary is a non-invasive measurement. The aim of this study was to elucidate whether bladder diary is a good surrogate for diagnosing bladder oversensitivity.

Detailed Description
-----------------
Between July 2009 and December 2020, medical records of all women with lower urinary tract symptoms but without cystocele who visited the urogynecological department of a medical center for urodynamic evaluation were reviewed. Those women who have no complete data of a 3-day bladder diary were excluded from this study. Bladder oversensitivity was diagnosed if the volume of strong desire was less than 300mL. We compared the urodynamic parameters to bladder diary parameters in order to find the best correlation between these 2 measurements for the diagnosis of bladder oversensitivity. STATA software was used for statistical analysis. Chi2 test, univariate and multivariable logistic regression tests were used for statistical analysis as appropriate. A p < 0.05 was considered as statistically significant.

Official Title
-----------------
Bladder Diary Can be a Good Surrogate of Diagnosing Bladder Oversensitivity

Conditions
-----------------
Bladder Oversensitivity

Intervention / Treatment
-----------------
* Diagnostic Test: Three-day bladder diary


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with lower urinary tract symptoms Complete a urodynamic study Complete a 3-day bladder diary Exclusion Criteria: Women with cystocele Chronic infection Incomplete data

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with lower urinary tract symptoms<br>Women with lower urinary tract symptoms without cystocele were included. | Diagnostic Test: Three-day bladder diary<br>* A three-day bladder diary for recording voiding-flow pattern of a women<br>* Other names: Urodynamic study;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between parameters | Correlation between 3-day bladder diary and urodynamic parameters | July 2009 to December 2020 |
The Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether sacral surface electrical stimulation is effective in the treatment of assisted reproductive technology.

Official Title
-----------------
Study of the Effect of Sacral Surface Electrical Stimulation for Assisted Reproductive Technology

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Device: SSE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of infertility
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sacral Surface Electrical (SSE)<br> | Device: SSE<br>* Use of SSE or not use of SSE<br>|
| No Intervention: control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| thickness of myometrium after embryo transfer |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| implantation rate |  | 3 years |
Advanced MRI Applications Development

Study Overview
=================
Brief Summary
-----------------
The goals of this study are to: To improve upon and develop new innovative magnetic resonance imaging techniques that refine image quality and enhance performance. Improvements in these areas will have positive implications for medical diagnosis and treatment. To correlate MRI images with underlying disease pathophysiology in order to ensure that imaging accurately reflects the disease process.

Official Title
-----------------
Advanced MRI Applications Development

Conditions
-----------------
Brain Tumors

Intervention / Treatment
-----------------
* Other: MRI scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Brain Tumor Exclusion Criteria: Unable to undergo MRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with brain tumors<br> | Other: MRI scan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients alive and progression free at 6 months |  | 6 months |
Promoting HIV Self-testing Among MSM During COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
A community-based organization (CBO) recruited Chinese-speaking men who have sex with men who are HIV-negative or unknown sero-status through multiple channels in Hong Kong, China. Participants first complete a baseline telephone survey, and then receive the following health promotion components: 1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO. All participants are invited to complete a follow-up telephone survey six months after completion of the baseline survey.

Official Title
-----------------
An Online Intervention Promoting Home-based HIV Self-testing Among Men Who Have Sex With Men in Hong Kong During the COVID-19 Pandemic

Conditions
-----------------
Health Behavior

Intervention / Treatment
-----------------
* Behavioral: Online interventions promoting HIV self-testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or above Having access to internet Anal intercourse with at least one man in the past six months Willing to complete telephone follow-up survey at Month 6 Exclusion Criteria: Self-reported to be HIV positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Online interventions promoting home-based HIV self-testing | Behavioral: Online interventions promoting HIV self-testing<br>* 1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HIV testing | Uptake of any type of HIV testing | 6 months | 
| HIV self-testing | Uptake of any type of home-based HIV self-testing | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV testing, HIV self-testing
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Study Overview
=================
Brief Summary
-----------------
Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.

Detailed Description
-----------------
The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.

Official Title
-----------------
Phase II Study of Intrathecal Ziconotide for the Treatment of Neuropathic Pain in Patients With Cancer

Conditions
-----------------
Pain, Neuropathic Pain, Intractable Pain, Cancer

Intervention / Treatment
-----------------
* Drug: ziconotide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of neoplasm Neuropathic pain level VASPI > or = 6 (0-10 scale) Inadequate pain relief with opioid analgesics and adjuvants Age > or = 18 years Performance status ECOG 0-2 Life expectancy at least one month Adequate contraception in women of child-bearing potential Signed Informed Consent Exclusion Criteria: Use of experimental drugs within previous 30 days Pregnancy or lactation Contraindication to the use of intrathecal analgesics, including active infection or conditions that could alter the circulation of cerebrospinal fluid Presence of cerebral metastasis INR > 2 Contraindication to the use of ziconotide Unable or unwilling to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: ziconotide<br>* intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate (> 30% reduction in VASPI) |  | 48 hours after completion of titration phase | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| toxicity |  | daily during drug titration, weekly thereafter | 
| duration of analgesic response |  | weekly |
National Tunisian Registry of Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
The National Tunisian Registry of Percutaneous Coronary Intervention is an observational, prospective and multicenter study aiming to assess coronary intervention strategies in tunisian departments of cardiology. Cardiologists from both sectors (public and private) are participating in the study, with 37 investigational centers. Data will be captured electronically by DACIMA Clinical Suite, according to FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPAA (Health Insurance Portability and Accountability Act) & ICH (International Conference on Harmonisation) requirements.

Official Title
-----------------
National Tunisian Registry of Percutaneous Coronary Intervention

Conditions
-----------------
ACS - Acute Coronary Syndrome, Angor Pectoris, Myocardial Infarction, Myocardial Ischemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tunisian patient needing PCI (Percutaneous Coronary Intervention) at the enrollment period Informed and signed consent Exclusion Criteria: Withdrawn consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MACE endopoint (Major adverse cardiovascular event) | Composite endpoint (MACE: major adverse cardiovascular event) : occurence of cardiovascular death, or non fatal myocardial infraction, or non fatal stroke, or Target Lesion revascularisation, or Target Vessel Revascularisation | Time-To-Event measure up to 12 months from baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death | Occurence of death incident (cardiovascular and non cardiovascular) | Time-To-Event measure up to 12 months from baseline | 
| PCI (Percutaneous Coronary Intervention) | PCI (Percutaneous Coronary Intervention) complications: any side effect event occuring per or post cardiac intervention | Time-To-Event measure up to 12 months from baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACS, PCI, MI
Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing In Vitro Fertilization (IVF)

Study Overview
=================
Brief Summary
-----------------
To assess the impact of embryo biopsy on the reproductive potential of human embryos.

Detailed Description
-----------------
This study will recruit patients from the NY/NJ/CT/eastern PA area only. All patients will undergo an in vitro fertilization (IVF) cycle with hormonal stimulation and an egg retrieval procedure as deemed appropriate for their diagnosis. Following biopsy, the embryos will be transferred. There will be no delay in the time of transfer as no cells will be analyzed prior to transfer. On day 3 or day 5 of embryo development, all patients will undergo a two (2) embryo transfer. The embryos selected for transfer will be the 2 morphologically best of the embryo cohort. Once selected for transfer, the embryos will be randomized so that one will be biopsied and the other will be transferred without undergoing biopsy. The embryo randomized to biopsy will have a single cell biopsied. Following delivery, buccal swabs will be collected from infants.

Official Title
-----------------
Evaluation of the Impact of Embryo Biopsy on the Reproductive Potential of Embryos Undergoing IVF

Conditions
-----------------
Each Patient is Both Case and Control, 1 Embryo Will be Biopsied and 1 Embryo is Not

Participation Criteria
=================
Eligibility Criteria
-----------------
This study will recruit patients from the NY/NJ/CT/eastern PA area only. Inclusion Criteria: Maximum of one prior failed IVF treatment cycle Female partner less than 35 years of age Normal day 3 FSH level (<10 miu/mL) Total basal antral follicle count greater than or equal to 12 Male partner with greater than 100,000 total motile spermatozoa and at least 1% normal forms Body mass index (BMI) < or = 32 Normal uterine cavity Exclusion Criteria: Diagnosis of chronic anovulation secondary to polycystic ovarian disease Diagnosis of endometrial insufficiency Clinical indication for pre-implantation genetic diagnosis (PGD) (undergoing IVF with PGD to rule out a known genetic defect) Use of testicular aspiration or biopsy procedures to obtain sperm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of biopsy on pregnancy | Impact of the biopsy of the embryo on whether a pregnancy is obtained | 1 year | 
| Impact of biopsy on delivery | Impact of the biopsy on pregnancy resulting in delivery | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PGD, IVF